Comparison 17. Hyalgan versus conventional therapy (three courses of treatment).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Pain overall (0‐100 mm VAS)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
1.1 45 to 52 weeks post‐injection	1	36	Mean Difference (IV, Fixed, 95% CI)	‐14.40 [‐31.86, 3.06]
2 Lequesne Index (0‐24)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
2.1 45 to 52 weeks post‐injection	1	36	Mean Difference (IV, Fixed, 95% CI)	‐0.90 [‐3.81, 2.01]
3 Joint space width (mm)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
3.1 45 to 52 weeks post‐injection	1	36	Mean Difference (IV, Fixed, 95% CI)	1.1 [‐0.01, 2.21]
4 Quality of life (AIMS: total of 12 items)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
4.1 45 to 52 weeks post‐injection	1	36	Mean Difference (IV, Fixed, 95% CI)	‐0.20 [‐0.98, 0.58]
5 Arthroscopy overall assessment (0‐100 mm VAS)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
5.1 45 to 52 weeks post‐injection	1	36	Mean Difference (IV, Fixed, 95% CI)	‐22.30 [‐40.52, ‐4.08]
6 SFA scoring (0‐100 mm VAS)	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
6.1 45 to 52 weeks post‐injection	1	36	Mean Difference (IV, Fixed, 95% CI)	‐18.2 [‐31.27, ‐5.13]
7 Safety: total withdrawals	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
7.1 45 to 52 weeks post‐injection	1	39	Risk Ratio (M‐H, Fixed, 95% CI)	0.48 [0.05, 4.82]